Mylan Nebivolol Hypertension Drug Patent Protection Expected Through 2015

Mylan expects to secure patent protection for the hypertension drug nebivolol until 2015, six years after the composition of matter patent expires, President and Chief Operating Officer Richard Moldin told analysts.